Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.

A 73-year-old is considering using Minoxidil or Dutasteride for hair loss. Suggestions include using RU58841, topical treatments, or unconventional methods like wigs and humorous, unrealistic remedies.

Increasing dutasteride from 3x to 5x a week led to worse hair loss and higher DHT levels, prompting a return to the original dosing. The user also uses topical minoxidil and is addressing a folic acid deficiency.

Hair follicles cannot be desensitized to DHT like allergies; treatments focus on reducing DHT levels or blocking its effects using methods like finasteride, GT20029, or PROTACs. Topical treatments like ceterizine and BPA application are also mentioned.

The conversation discusses elevated hormone levels after using Finasteride for 2 months and Dutasteride for 2 weeks for hair loss. Users suggest that increased testosterone and estradiol levels are expected due to DHT inhibition, and it's not a concern unless symptoms occur.

The conversation discusses the potential risks of introducing anabolic steroids, specifically trenbolone, during an active hair shedding phase caused by RU58841, while on TRT and low-dose finasteride. Users advise waiting for hair shedding to stabilize before adding new compounds, highlighting the potential for increased hair loss and health risks.

The conversation is about whether KX-826 is worth its high cost for hair loss treatment. Users suggest it may not justify the price, especially if already using minoxidil and finasteride.

A user experienced hair thinning after using tamoxifen and bupropion and is now using topical dutasteride, alfatradiol, melatonin, adenosine, and specific shampoos for improvement. They are considering using steroids and are seeking advice on whether combining oral dutasteride with TRT/PEDs would affect hair health, with mixed opinions on the impact of testosterone and DHT on hair loss.

Breezula is discussed as a potential topical anti-androgen treatment for hair loss, with mixed opinions on its effectiveness and side effects compared to other treatments like finasteride, minoxidil, and RU58841. Some users express skepticism about its long-term efficacy and potential side effects, while others are hopeful for its approval and use in combination with existing treatments.

A woman with androgenic hair loss, likely due to PCOS, is seeking topical treatments as oral medications are not an option. Suggested treatments include topical finasteride, spironolactone, and clascoterone, with spironolactone and clascoterone being safer options due to lower systemic absorption risk.

A new topical compound for hair loss, claimed to be developed by Jeff Vincint, is being discussed. It reportedly doesn't use minoxidil or finasteride, and there is skepticism about its legitimacy.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation discusses the effectiveness of using 2.5 mg Dutasteride daily versus combining 0.5 mg Dutasteride with 150 mg RU58841 for reducing scalp DHT. Opinions vary, with some users recommending lower doses of Dutasteride and cautioning against RU58841 due to potential side effects.

Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

DHT, not testosterone, causes hair loss. Treatments like finasteride, dutasteride, and RU58841 target DHT to manage hair loss.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

Using estrogen for hair regrowth is considered ineffective and risky, with potential side effects like breast growth and hormonal changes. Alternatives like finasteride, dutasteride, and minoxidil are suggested, but estrogen is not recommended unless transitioning.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Minoxidil is not an anti-androgen; it is a growth stimulator and does not lower DHT like finasteride or dutasteride. Minoxidil can cause side effects like facial swelling and anxiety due to its vasodilator properties.

Topical finasteride can effectively reduce scalp DHT by targeting local enzymes, despite less systemic impact compared to oral forms. Combining oral dutasteride with topical finasteride and minoxidil may enhance hair loss prevention, though evidence of its effectiveness is limited.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

A 21-year-old male has been experiencing persistent hair loss despite using treatments like dutasteride, finasteride, RU58841, minoxidil, and ketoconazole. Suggestions include checking for hormonal issues, nutritional deficiencies, or allergies, and consulting a doctor for professional advice.

The user is using oral finasteride and minoxidil 2mg for hair loss and is considering adding a scalp serum with caffeine, but is concerned it might interfere with minoxidil. They seek advice on maintaining a hydrated, non-oily scalp.